Clinical Experience with Berotralstat in Patients with Hereditary Angioedema with Normal C1-Esterase Inhibitor: A Commented Case Series

References

• Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132–150 e3. doi:10.1016/j.jaip.2020.08.046
   PubMed Web of Science ®Google Scholar
• Caballero T. Treatment of hereditary angioedema. J Investig Allergol Clin Immunol. 2021;31(1):1–16. doi:10.18176/jiaci.0653
   PubMed Web of Science ®Google Scholar
• Longhurst HJ, Bork K. Hereditary angioedema: an update on causes, manifestations and treatment. Br J Hosp Med. 2019;80(7):391–398. doi:10.12968/hmed.2019.80.7.391
   PubMed Web of Science ®Google Scholar
• Bork K, Machnig T, Wulff K, Witzke G, Prusty S, Hardt J. Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence. Orphanet J Rare Dis. 2020;15(1):289. doi:10.1186/s13023-020-01570-x
   PubMed Web of Science ®Google Scholar
• Jones DH, Bansal P, Bernstein JA, et al. Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor. World Allergy Organ J. 2022;15(1):100621. doi:10.1016/j.waojou.2021.100621
   PubMed Web of Science ®Google Scholar
• Riedl MA. Hereditary angioedema with normal C1-INH (HAE type III). J Allergy Clin Immunol Pract. 2013;1(5):427–432. doi:10.1016/j.jaip.2013.06.004
   PubMed Web of Science ®Google Scholar
• Magerl M, Germenis AE, Maas C, Maurer M. Hereditary angioedema with normal C1 inhibitor: update on evaluation and treatment. Immunol Allergy Clin North Am. 2017;37(3):571–584. doi:10.1016/j.iac.2017.04.004
   PubMed Web of Science ®Google Scholar
• Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema - the 2021 revision and update. Allergy. 2022;77(7):1961–1990. doi:10.1111/all.15214
   PubMed Web of Science ®Google Scholar
• Bork K, Wulff K, Möhl BS, et al. Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation. J Allergy Clin Immunol. 2021;148(4):1041–1048. doi:10.1016/j.jaci.2021.01.011
   PubMed Web of Science ®Google Scholar
• Henao MP, Kraschnewski JL, Kelbel T, Craig TJ. Diagnosis and screening of patients with hereditary angioedema in primary care. Ther Clin Risk Manag. 2016;12:701–711. doi:10.2147/TCRM.S86293
   PubMed Web of Science ®Google Scholar
• Farkas H, Martinez‐Saguer I, Bork K, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy. 2017;72(2):300–313. doi:10.1111/all.13001
   PubMed Web of Science ®Google Scholar
• Bork K, Wulff K, Hardt J, Witzke G, Staubach P. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol. 2009;124(1):129–134. doi:10.1016/j.jaci.2009.03.038
   PubMed Web of Science ®Google Scholar
• Deroux A, Boccon-Gibod I, Fain O, et al. Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the French National Center of Reference for Angioedema. Clin Exp Immunol. 2016;185(3):332–337. doi:10.1111/cei.12820
   PubMed Web of Science ®Google Scholar
• Bova M, Suffritti C, Bafunno V, et al. Impaired control of the contact system in hereditary angioedema with normal C1‐inhibitor. Allergy. 2020;75(6):1394–1403. doi:10.1111/all.14160
   PubMed Web of Science ®Google Scholar
• Bork K, Gül D, Hardt J, Dewald G. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med. 2007;120(11):987–992. doi:10.1016/j.amjmed.2007.08.021
   PubMed Web of Science ®Google Scholar
• Bork K. Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor. Allergy Asthma Clin Immunol. 2010;6(1):15. doi:10.1186/1710-1492-6-15
   PubMedGoogle Scholar
• Banday AZ, Kaur A, Jindal AK, Rawat A, Singh S. An update on the genetics and pathogenesis of hereditary angioedema. Genes Dis. 2020;7(1):75–83. doi:10.1016/j.gendis.2019.07.002
   PubMed Web of Science ®Google Scholar
• Zanichelli A, Longhurst HJ, Maurer M, et al. Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting. Ann Allergy Asthma Immunol. 2016;117(4):394–398. doi:10.1016/j.anai.2016.08.014
   PubMed Web of Science ®Google Scholar
• Lara‐Marquez ML, Christiansen SC, Riedl MA, Herschbach J, Zuraw BL. Threshold‐stimulated kallikrein activity distinguishes bradykinin‐ from histamine‐mediated angioedema. Clin Exp Allergy. 2018;48(11):1429–1438. doi:10.1111/cea.13219
   PubMed Web of Science ®Google Scholar
• Bouillet L, Boccon‐Gibod I, Launay D, et al. Hereditary angioedema with normal C1 inhibitor in a French cohort: clinical characteristics and response to treatment with icatibant. Immun Inflamm Dis. 2017;5(1):29–36. doi:10.1002/iid3.137
   PubMed Web of Science ®Google Scholar
• BioCryst Pharmaceuticals, Inc. ORLADEYO™ (berotralstat) capsules, for oral use – highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf. Accessed November 8, 2022.
   Google Scholar
• European Medicines Agency. Summary of opinion (initial authorisation): Orladeyo: berotralstat. Available from: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-orladeyo_en.pdf. Accessed November 8, 2022.
   Google Scholar
• Kelbel T. A case of normal C1 esterase inhibitor hereditary angioedema successfully treated with berotralstat. Ann Allergy Asthma Immunol. 2022;128(4):462–463. doi:10.1016/j.anai.2022.01.014
   PubMed Web of Science ®Google Scholar
• Riedl MA, Banerji A, Gower R. Current medical management of hereditary angioedema: follow-up survey of US physicians. Ann Allergy Asthma Immunol. 2021;126(3):264–272. doi:10.1016/j.anai.2020.10.009
   PubMed Web of Science ®Google Scholar
• Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE Guidelines: consensus-based Clinical Case Reporting Guideline Development. Glob Adv Health Med. 2013;2(5):38–43. doi:10.7453/gahmj.2013.008
   PubMedGoogle Scholar
• Maurer M, Magerl M. Differences and similarities in the mechanisms and clinical expression of bradykinin-mediated vs mast cell-mediated angioedema. Clin Rev Allergy Immunol. 2021;61(1):40–49. doi:10.1007/s12016-021-08841-w
   PubMed Web of Science ®Google Scholar
• Zuraw BL, Bork K, Binkley KE, et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc. 2012;33(Suppl 1):S145–S156. doi:10.2500/aap.2012.33.3627
   PubMed Web of Science ®Google Scholar
• Riedl MA, Danese M, Danese S, Ulloa J, Maetzel A, Audhya PK. Hereditary angioedema with normal C1 inhibitor: US Survey of Prevalence and Provider Practice Patterns. J Allergy Clin Immunol Pract. 2023;11(8):2450–2456 e6. doi:10.1016/j.jaip.2023.01.023
   PubMed Web of Science ®Google Scholar
• Kerkar P. What is the C1 esterase inhibitor test and why is it ordered? Available from: https://www.epainassist.com/test-and-procedures/what-is-the-c1-esterase-inhibitor-test. Accessed November 8, 2022.
   Google Scholar
• Salguero CAS, Chacon AIS. HAE in children- what is the best treatment strategy? Approval of a drug. Int J Aller Medications. 2016;2(1):16. doi:10.23937/2572-3308.1510016
   Google Scholar